Clinical Trials
34 trialsAdjuvant WIDER
Novartis
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
e3
SWOG Cancer Research Network
AMEERA-5
Sanofi
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Eurofarma Laboratorios S.A.
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
PATHWAY
National Cancer Center, Japan
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
COMPLEEMENT-1
Novartis
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
SAFIA
International Cancer Research Group, United Arab Emirates
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
LARES
AstraZeneca
COMPETE
Ruijin Hospital
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
SWOG Cancer Research Network
Study to Compare Zoladexâ„¢ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
AstraZeneca
POF
Peking Union Medical College Hospital
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
Fudan University
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
M.D. Anderson Cancer Center
Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
King Faisal Specialist Hospital & Research Center
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Peking Union Medical College Hospital
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
National Cancer Institute (NCI)
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
PROOF
AstraZeneca
ASTRRA
Korean Breast Cancer Study Group